Literature DB >> 9335446

Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.

G Launoy1, T C Smith, S W Duffy, V Bouvier.   

Abstract

Mass screening using the faecal occult blood test (FOBT) can reduce mortality from colorectal cancer. Reliable estimation of FOBT sensitivity is crucial in assessing the potential effectiveness of a mass-screening procedure. Available estimates could be inaccurate because they neglect the temporal aspect of screening. The aim of our study was to estimate the sensitivity of the FOBT in mass screening for colorectal cancer, taking into account the duration of the pre-clinical phase of the disease assessed by the mean sojourn time (MST), and to assess whether MST and FOBT sensitivity differ according to cancer subsite. We analysed data taken from the first round of the mass-screening programme of the department of Calvados (France), involving 164,364 subjects of whom 43.4% participated in FOB screening. MST and sensitivity were estimated using a simple empirical approach, a traditional maximum likelihood method and log-linear modelling using the Bayesian technique of Gibbs sampling. MST was estimated as between 4.5 and 5 years for all subsites combined. According to the Gibbs sampling method, MSTs were 3.5, 6.4 and 2.6 years for proximal colon, distal colon and rectal cancer, respectively. Our estimation methods give a low sensitivity for the FOBT (50%), results for different subsites being closer to each other, slightly higher for proximal cancer. Our results strongly suggest that tumour growth rates are very different according to subsite, slowest for distal cancer and speediest for rectal cancer. Consideration of FOBT sensitivity without MST appears unreliable. Our results by subsite suggest that combining FOBT and sigmoidoscopy could be a good strategy for colorectal cancer screening.

Entities:  

Mesh:

Year:  1997        PMID: 9335446     DOI: 10.1002/(sici)1097-0215(19971009)73:2<220::aid-ijc10>3.0.co;2-j

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.

Authors:  Wang-Yang Chen; Xiao-Juan Zhao; Zhi-Fu Yu; Fu-Lan Hu; Yu-Peng Liu; Bin-Bin Cui; Xin-Shu Dong; Ya-Shuang Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis.

Authors:  Scott D Ramsey; Wylie Burke; Linda Pinsky; Lauren Clarke; Polly Newcomb; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-11       Impact factor: 4.254

3.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.

Authors:  Ann G Zauber; Sidney J Winawer; Michael J O'Brien; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Benjamin F Hankey; Weiji Shi; John H Bond; Melvin Schapiro; Joel F Panish; Edward T Stewart; Jerome D Waye
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

4.  Multistate models for the natural history of cancer progression.

Authors:  Li C Cheung; Paul S Albert; Shrutikona Das; Richard J Cook
Journal:  Br J Cancer       Date:  2022-07-11       Impact factor: 9.075

5.  Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.

Authors:  Wenying Zheng; Carolyn M Rutter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-21       Impact factor: 4.254

6.  A projection of benefits due to fecal occult blood test for colorectal cancer.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Cancer Epidemiol       Date:  2009-09-04       Impact factor: 2.984

7.  Individualizing colonoscopy screening by sex and race.

Authors:  Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Ann G Zauber; Rob Boer; Janneke Wilschut; Sidney J Winawer; J Dik F Habbema
Journal:  Gastrointest Endosc       Date:  2009-05-24       Impact factor: 9.427

8.  Evaluating risk factor assumptions: a simulation-based approach.

Authors:  Carolyn M Rutter; Diana L Miglioretti; James E Savarino
Journal:  BMC Med Inform Decis Mak       Date:  2011-09-07       Impact factor: 2.796

9.  Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.

Authors:  Grace Hui-Min Wu; Yi-Ming Wang; Amy Ming-Fang Yen; Jau-Min Wong; Hsin-Chih Lai; Jane Warwick; Tony Hsiu-Hsi Chen
Journal:  BMC Cancer       Date:  2006-05-24       Impact factor: 4.430

10.  Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location.

Authors:  L Guittet; V Bouvier; N Mariotte; J P Vallee; R Levillain; J Tichet; G Launoy
Journal:  Br J Cancer       Date:  2009-03-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.